Dupilumab Update: Phase 3 Trial for Children 6-11 Years

Week 16: Efficacy

	Overall			
	Placebo + TCS (n = 61)	300 mg Q4W + TCS (n = 61)	Placebo + TCS (n = 62)	200 mg Q2W + TCS (n = 59)
	< 30 kg	< 30 kg	≥ 30 kg	≥ 30 kg
Proportion of patients with EASI-75, %	28	75	26	75

Week 16: Safety

	Overall			
	Placebo + TCS (n = 60)	300 mg Q4W + TCS (n = 60)	Placebo + TCS (n = 60)	200 mg Q2W + TCS (n = 59)
	< 30 kg	< 30 kg	≥ 30 kg	≥ 30 kg
Conjunctivitis cluster, n (%)	2 (3.3)	4 (6.7)	3 (5.0)	5 (8.5)
Injection-site reactions, n (%)	4 (6.7)	6 (10)	3 (5.0)	8 (13.6)

Warnings from the package insert include hypersensitivity, and conjunctivitis and keratitis

Paller AS, et al. *J Am Acad Dermatol.* 2020. [Epub ahead of print];
Dupilumab. Package insert. Regeneron Pharmaceuticals, Inc./Sanofi Genzyme; 2020.

JAK/STAT Inhibitors: Abrocitinib Update

Week 12: Efficacy

	Placebo (n = 77)	Abrocitinib 200 mg (n = 154)	Abrocitinib 100 mg (n = 155)
Proportion of patients with EASI-75, n (%)	8 (10.4)	94 (61.0); *P* < .001	69 (44.5); *P* < .001

Week 12: Safety

	Placebo (n = 78)	Abrocitinib 200 mg (n = 155)	Abrocitinib 100 mg (n = 158)
Nausea, n (%)	2 (2.6)	22 (14.2)	12 (7.6)
Nasopharyngitis, n (%)	5 (6.4)	12 (7.7)	20 (12.7)
Headache, n (%)	2 (2.6)	12 (7.7)	9 (5.7)

Silverberg J, et al. *JAMA Dermatol.* 2020;156:1-11.

JAK/STAT Inhibitors: Baricitinib Update

Week 16: Efficacy (monotherapy)

	Placebo (n = 249)	Baricitinib 4 mg (n = 125)	Baricitinib 2 mg (n = 123)	Baricitinib 1 mg (n = 121)
Proportion of patients with EASI-75, %	8.8	24.8; *P* < .001	18.7; *P* < .01	17.3; *P* < .05

Week 16: Safety

	Placebo (n = 249)	Baricitinib 4 mg (n = 125)	Baricitinib 2 mg (n = 123)	Baricitinib 1 mg (n = 127)
Nasopharyngitis, n (%)	26 (10.4)	12 (9.6)	12 (9.8)	22 (17.3)
Headache, n (%)	16 (6.4)	10 (8)	14 (11.4)	7 (5.5)

Simpson EL, et al. *Br J Dermatol.* 2020;183:242-55.

JAK/STAT Inhibitors: Upadacitinib Update

Week 16: Efficacy

	Placebo (n = 41)	Upadacitinib 7.5 mg QD (n = 42)	Upadacitinib 15 mg QD (n = 42)	Upadacitinib 30 mg QD (n = 42)
Mean improvement from baseline in EASI, %	23	39; *P* = .03	62; *P* < .001	74; *P* < .001

Week 16: Safety

	Placebo (n = 40)	Upadacitinib 7.5 mg QD (n = 42)	Upadacitinib 15 mg QD (n = 42)	Upadacitinib 30 mg QD (n = 42)
Upper respiratory tract infections, n (%)	4 (10)	7 (17)	5 (12)	5 (12)
AD worsening, n (%)	2 (5)	6 (14)	2 (4.8)	4 (9.5)
Acne, n (%)	1 (2.5)	4 (9.5)	2 (4.8)	6 (14)

Guttman-Yassky E, et al. *J Allergy Clin Immunol.* 2020;145:877-84.

Biologics in Development: Tralokinumab

Week 16: Efficacy

	Placebo	Tralokinumab
IGA 0 or 1 (ECZTRA 1)	14/197 (7.1%)	95/601 (15.8%); *P* < .01
IGA 0 or 1 (ECZTRA 2)	22/201 (10.9%)	131/591 (22.2%); *P* < .001

Week 16: Safety

	ECZTRA 1		ECZTRA 2	
AEs reported by ≥ 5% of patients in any treatment group	Placebo (n = 196)	Tralokinumab 300 mg Q2W (n = 602)	Placebo (n = 200)	Tralokinumab 300 mg Q2W (n = 592)
Viral upper respiratory tract infection, n (%)	41 (21)	139 (23)	17 (9)	49 (8)
Conjunctivitis, n (%)	4 (2)	43 (7)	3 (2)	18 (3)

Simpson EL, et al. Presented at AAD 2020.

Biologics in Development: Lebrikizumab

Week 16: Efficacy

	Dosage			
	Placebo Q2W (n = 52)	250 mg Q2W (n = 75)	250 mg Q4W (n = 80)	125 mg Q4W (n = 73)
EASI-75, % (*P* value, compared with placebo)	24.3%	60.6% (< .001)	56.1% (.002)	43.3% (.06)
Pruritus NRS score Least squares % change from baseline (*P* value)	+4.3%	-60.6% (< .001)	-49.6% (< .001)	-35.9% (.005)

Week 16: Safety

	Dosage			
	Placebo Q2W (n = 52)	250 mg Q2W (n = 75)	250 mg Q4W (n = 80)	125 mg Q4W (n = 73)
Upper respiratory tract infection, n (%)	3 (5.8)	2 (2.7)	9 (11.3)	6 (8.2)
Nasopharyngitis, n (%)	2 (3.8)	9 (12)	2 (2.5)	4 (5.5)

Guttman-Yassky E, et al. *JAMA Dermatol.* 2020;156:411-20.

Biologics in Development: Nemolizumab

Week 16: Efficacy

	Placebo (n = 72)	Nemolizumab (n = 143)
Mean percent change in the EASI score	-33.2%	-45.9%

Week 16: Safety

	Placebo (n = 72)	Nemolizumab (n = 143)
Injection-site reactions	3%	8%

Kabashima K, et al. *N Engl J Med.* 2020;383:141-50.